Cancer / Tumor Profiling

Global Cancer / Tumor Profiling Market to Reach US$21.3 Billion by 2030

The global market for Cancer / Tumor Profiling estimated at US$12.1 Billion in the year 2024, is expected to reach US$21.3 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Immunoassays, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the Next Generation Sequencing segment is estimated at 10.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.1 Billion While China is Forecast to Grow at 10.6% CAGR

The Cancer / Tumor Profiling market in the U.S. is estimated at US$4.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.8% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Cancer / Tumor Profiling Market - Key Trends & Drivers Summarized

The advent of molecular profiling, driven by genomics and next-generation sequencing (NGS), is revolutionizing personalized cancer treatment. By using tissue samples and less invasive liquid biopsies, molecular profiling identifies genetic mutations and fusions that are crucial for personalized cancer therapies. In recent years, the application of DNA/RNA sequencing on formalin-fixed, paraffin-embedded (FFPE) tissues significantly enhanced the ability to pinpoint actionable targets within tumors. Nevertheless, having a druggable target does not necessarily ensure its role in disease progression or clinical efficacy. Effective molecular profiling necessitates advanced technical skills and a profound understanding of tumor biology and associated therapies, especially in cases lacking standardized treatments where NGS provides alternative therapeutic options.

Tumor profiling offers comprehensive insights into the genetic landscape of cancers, facilitating the development of targeted therapies aimed at specific genetic alterations. This approach notably transformed the treatment of lung cancer, with therapies targeting EGFR mutations being among the earliest successful examples. Beyond pinpointing individual mutations, profiling elucidates the broader molecular framework of cancer progression and resistance mechanisms, paving the way for combination therapies to combat resistance. Additionally, the identification of biomarkers through profiling can predict patient responses to immunotherapy, enabling more personalized treatment regimens. The integration of liquid biopsy techniques, such as ctDNA and CTC analysis, further augments profiling capabilities, allowing non-invasive, real-time monitoring of tumor dynamics and minimal residual disease.

The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.

SCOPE OF STUDY:

The report analyzes the Cancer / Tumor Profiling market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry, Other Technologies); Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer Types); Application (Research Application, Clinical Application)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 55 Featured) -

• Agilent Technologies, Inc.
• Caris Life Sciences
• Exact Sciences Corporation
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina SAPAC
• IMB Dx, Inc.
• Lucence Health, Inc.
• NeoGenomics Laboratories Inc.
• Roche Sequencing Solutions, Inc.
• Sysmex Corporation
• Tempus Labs
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.